Lisa Baumbach-Reardon
University of Miami
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lisa Baumbach-Reardon.
American Journal of Human Genetics | 2008
Juliane Ramser; Mary Ellen Ahearn; Claus Lenski; Kemal O. Yariz; Heide Hellebrand; Michael von Rhein; Robin D. Clark; Rita K. Schmutzler; Peter Lichtner; Eric P. Hoffman; Alfons Meindl; Lisa Baumbach-Reardon
X-linked infantile spinal muscular atrophy (XL-SMA) is an X-linked disorder presenting with the clinical features hypotonia, areflexia, and multiple congenital contractures (arthrogryposis) associated with loss of anterior horn cells and infantile death. To identify the XL-SMA disease gene, we performed large-scale mutation analysis in genes located between markers DXS8080 and DXS7132 (Xp11.3-Xq11.1). This resulted in detection of three rare novel variants in exon 15 of UBE1 that segregate with disease: two missense mutations (c.1617 G-->T, p.Met539Ile; c.1639 A-->G, p.Ser547Gly) present each in one XL-SMA family, and one synonymous C-->T substitution (c.1731 C-->T, p.Asn577Asn) identified in another three unrelated families. Absence of the missense mutations was demonstrated for 3550 and absence of the synonymous mutation was shown in 7914 control X chromosomes; therefore, these results yielded statistical significant evidence for the association of the synonymous substitution and the two missense mutations with XL-SMA (p = 2.416 x 10(-10), p = 0.001815). We also demonstrated that the synonymous C-->T substitution leads to significant reduction of UBE1 expression and alters the methylation pattern of exon 15, implying a plausible role of this DNA element in developmental UBE1 expression in humans. Our observations indicate first that XL-SMA is part of a growing list of neurodegenerative disorders associated with defects in the ubiquitin-proteasome pathway and second that synonymous C-->T transitions might have the potential to affect gene expression.
Journal of Clinical Investigation | 2012
Gladys Montenegro; Adriana P. Rebelo; James W. Connell; Rachel Allison; Carla Babalini; Michela D’Aloia; Pasqua Montieri; Rebecca Schüle; Hiroyuki Ishiura; Justin Price; Alleene V. Strickland; Michael Gonzalez; Lisa Baumbach-Reardon; Tine Deconinck; Jia Huang; Giorgio Bernardi; Jeffery M. Vance; Mark T. Rogers; Shoji Tsuji; Margaret A. Pericak-Vance; Ludger Schöls; Antonio Orlacchio; Evan Reid; Stephan Züchner
Hereditary spastic paraplegias (HSPs) are a group of genetically heterogeneous neurodegenerative conditions. They are characterized by progressive spastic paralysis of the legs as a result of selective, length-dependent degeneration of the axons of the corticospinal tract. Mutations in 3 genes encoding proteins that work together to shape the ER into sheets and tubules - receptor accessory protein 1 (REEP1), atlastin-1 (ATL1), and spastin (SPAST) - have been found to underlie many cases of HSP in Northern Europe and North America. Applying Sanger and exome sequencing, we have now identified 3 mutations in reticulon 2 (RTN2), which encodes a member of the reticulon family of prototypic ER-shaping proteins, in families with spastic paraplegia 12 (SPG12). These autosomal dominant mutations included a complete deletion of RTN2 and a frameshift mutation predicted to produce a highly truncated protein. Wild-type reticulon 2, but not the truncated protein potentially encoded by the frameshift allele, localized to the ER. RTN2 interacted with spastin, and this interaction required a hydrophobic region in spastin that is involved in ER localization and that is predicted to form a curvature-inducing/sensing hairpin loop domain. Our results directly implicate a reticulon protein in axonopathy, show that this protein participates in a network of interactions among HSP proteins involved in ER shaping, and further support the hypothesis that abnormal ER morphogenesis is a pathogenic mechanism in HSP.
Genetics in Medicine | 2007
Devin Dressman; Mary Ellen Ahearn; Kemal O. Yariz; Hugo Basterrecha; Francisco Venegas Martínez; Francesc Palau; Michael Barmada; Robin D. Clark; Alfons Meindl; Brunhilde Wirth; Eric P. Hoffman; Lisa Baumbach-Reardon
Purpose: X-linked infantile spinal-muscular atrophy (XL-SMA) is a rare disorder, which presents with the clinical characteristics of hypotonia, areflexia, and multiple congenital contractures (arthrogryposis) associated with loss of anterior horn cells and death in infancy. We have previously reported a single family with XL-SMA that mapped to Xp11.3-q11.2. Here we report further clinical description of XL-SMA plus an additional seven unrelated (XL-SMA) families from North America and Europe that show linkage data consistent with the same region.Methods: We first investigated linkage to the candidate disease gene region using microsatellite repeat markers. We further saturated the candidate disease gene region using polymorphic microsatellite repeat markers and single nucleotide polymorphisms in an effort to narrow the critical region. Two-point and multipoint linkage analysis was performed using the Allegro software package.Results: Linkage analysis of all XL-SMA families displayed linkage consistent with the original XL-SMA region.Conclusion: The addition of new families and new markers has narrowed the disease gene interval for a XL-SMA locus between SNP FLJ22843 near marker DXS 8080 and SNP ARHGEF9 which is near DXS7132 (Xp11.3-Xq11.1).
Heart Rhythm | 2013
Michael Hoosien; Mary Ellen Ahearn; Robert J. Myerburg; Thai V. Pham; Todd Miller; Marcel J.D. Smets; Lisa Baumbach-Reardon; Ming Lon Young; Amjad Farooq; Nanette H. Bishopric
BACKGROUND The slowly-activating delayed rectifier current IKs contributes to repolarization of the cardiac action potential, and is composed of a pore-forming α-subunit, KCNQ1, and a modulatory β-subunit, KCNE1. Mutations in either subunit can cause long QT syndrome, a potentially fatal arrhythmic disorder. How KCNE1 exerts its extensive control over the kinetics of IKs remains unresolved OBJECTIVE To evaluate the impact of a novel KCNQ1 mutation on IKs channel gating and kinetics METHODS KCNQ1 mutations were expressed in Xenopus oocytes in the presence and absence of KCNE1. Voltage clamping and MODELLER software were used to characterize and model channel function. Mutant and wt genes were cloned into FLAG, Myc and HA expression vectors to achieve differential epitope tagging, and expressed in HEK293 cells for immunohistochemical localization and surface biotinylation assay. RESULTS We identified 2 adjacent mutations, S338F and F339S, in the KCNQ1 S6 domain in unrelated probands. The novel KCNQ1 S338F mutation segregated with prolonged QT interval and torsade de pointes; the second variant, F339S, was associated with fetal bradycardia and prolonged QT interval, but no other clinical events. S338F channels expressed in Xenopus oocytes had slightly increased peak conductance relative to wild type, with a more positive activation voltage. F339S channels conducted minimal current. Unexpectedly, S338F currents were abolished by co-expression with intact WT KCNE1 or its C-terminus (aa63-129), despite normal membrane trafficking and surface co-localization of KCNQ1 S338F and wt KCNE1. Structural modeling indicated that the S338F mutation specifically alters the interaction between the S6 domain of one KCNQ1 subunit and the S4-S5 linker of another, inhibiting voltage-induced movement synergistically with KCNE1 binding. CONCLUSIONS A novel KCNQ1 mutation specifically impaired channel function in the presence of KCNE1. Our structural model shows that this mutation effectively immobilizes voltage gating by an inhibitory interaction that is additive with that of KCNE1. Our findings illuminate a previously unreported mechanism for LQTS, and validate recent theoretical models of the closed state of the KCNQ1:KCNE1 complex.
Nature Genetics | 2001
Lisa Baumbach-Reardon; Luis Gayol; Tom Scholl; Hugo Basterrechea; Selina Smith; J. Fernando Arena
Completed BRCA1/BRCA2 mutation analysis reveals a low rate of germline mutation in at-risk African American families
Archive | 2012
Lisa Baumbach-Reardon; Stephanie Sacharow; Mary Ellen Ahearn
Cancer Epidemiology and Prevention Biomarkers | 2007
Lisa Baumbach-Reardon; Mary Ellen Ahearn; Merce Jorda; Carmen Gomez; Tom Halsey; Jim Yan; Kevin Ellison; Stefan Glück
Archive | 2003
Jose F. Arena; Lisa Baumbach-Reardon; Luis Gayol; Mary Ellen Ahearn
Cancer Research | 2018
Lisa Baumbach-Reardon; Julie E. Getz; Mary Ellen Ahearn; John D. Carpten; Mark D. Pegram
Archive | 2012
Lisa Baumbach-Reardon; Stephanie Sacharow; Mary Ellen Ahearn